Thalassemia and Sickle Cell Anaemia are common genetic disorders, with options for treatment and prevention available.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Thalassemia and sickle cell anaemia are common genetic disorders in India. Early testing, prenatal screening, and improved ...

the first CRISPR/Cas9 gene-editing therapy in the UAE. This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion ...

and transfusion dependent beta-thalassemia (TDT), positioning Abu Dhabi as a leading destination for life sciences and is a significant achievement in the field of innovation and gene therapies.

Norah Awad has lived with beta thalassemia major, a severe blood disorder that has required monthly transfusions since she ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

LentiGlobin BB305 aims to treat beta-thalassemia major and severe sickle cell disease ... a single treatment of the gene therapy corrected the main genetic defect which causes the condition.

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...